Merck KGaA projects much higher income for 2013; Biogen raises forecast; Shires settle suit over ADHD drug;

@FiercePharma: Trending at European regulators tag 100-plus drugs with 'black triangle.' Article | Follow @FiercePharma

@EricPFierce: Ipsen warns of shortages of its orphan drug Increlex. Story | Follow @EricPFierce

> Germany's Merck KGaA CEO Karl-Ludwig Kley Friday reconfirmed the expectation that 2013 net income will increase significantly. Item

> Biogen Idec ($BIIB) raised its earnings projections for the year after its first quarter results bested expectations. Story

> Shire ($SHPG) has settled patent litigation with Actavis ($ACT), allowing it to sell a generic version of Shire's ADHD drug Intuniv. Story

> FDA would get the control over some compounding pharmacies that it wants under new legislation offered up Friday. Story

> The largest and most advanced study for a vaccine to prevent HIV infection was halted by the U.S. after an interim look at the data showed it was unlikely to help recipients. Story

Medical Device News

@FierceMedDev: FDA wants more data on Insuline's pump. Article | Follow @FierceMedDev

@MarkHFierce: Now this is just cool: Carnegie Mellon U. folks are developing med devices you would swallow and partially digest. More | Follow @MarkHFierce

 @DamianFierce: A spike in restructuring costs slashed Covidien's profits, despite a revenue jump. Story | Follow @DamianFierce

> Insuline pump hits FDA obstacle. Item

> Life Tech shareholder sues over $13.6B Thermo buyout. Report

> VC giant NEA backs Topera in $25M Series C. Article

Biotech News

@FierceBiotech: NIH stops HIV vaccine trial after immunizations fail. Story | Follow @FierceBiotech

@JohnCFierce: So EU doesn't like Pfizer's Xeljanz at all. That's a blow. More | Follow @JohnCFierce

@RyanMFierce: Industry Voices: Time to Take Fecal Transplantation Seriously. Article | Follow @RyanMFierce

> Biotech startup hustles new Alzheimer's program to the clinic. News

> Johnson & Johnson, Evotec bask in Harvard's breaking diabetes discovery. Article

> Biotech Receptos trots out terms for $71M IPO. Item

> Theravance to split into two biotech groups as GSK drugs progress. More

And Finally... A Novartis ($NVS) plant in Switzerland that makes OTC products that had been slated for closure will now be expanded. Story